Physician profile
Jay R Schachner
NPI 1962444810
$3,340.17
in general payments reported to CMS, 2019-2025
49 companies · $2,077 in 2025
The $2,077 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $320 · 2020: $16.93 · 2023: $145 · 2024: $781 · 2025: $2,077.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,775 · Education: $228.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,775.34 |
| Education | $228.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $345.47 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $327.09 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $190.05 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $182.81 | 2020-2025 | Opdivo, Opdualag |
| Celgene Corporation | $175.00 | 2024-2025 | Opdualag, Reblozyl, Opdivo |
| Astellas Pharma US INC | $171.44 | 2023-2025 | Xtandi, Padcev, Vyloy |
| Astrazeneca Pharmaceuticals LP | $158.20 | 2025 | Enhertu, Calquence, Imfinzi |
| Sobi, INC | $126.73 | 2024-2025 | |
| Daiichi Sankyo INC. | $117.21 | 2024-2025 | Enhertu, Vanflyta |
| Merck Sharp & Dohme LLC | $112.14 | 2024-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Janssen Biotech, INC. | $111.29 | 2025 | Talvey, Tecvayli, Darzalex |
| Tempus Ai, INC | $103.74 | 2024-2025 | Xt Cdx |
| Abbvie INC. | $74.86 | 2025 | |
| Eisai INC. | $74.03 | 2024-2025 | |
| Glaxosmithkline, LLC. | $73.48 | 2025 | Ojjaara |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Schachner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.